Marinus Pharma (MRNS) – Press Releases
-
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
-
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
-
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
-
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study
-
Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
-
Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY® (ganaxolone) Oral Suspension CV
-
Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Marinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
-
Marinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst Event
-
Marinus Pharmaceuticals Announces Speakers for Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Marinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
-
Marinus Pharmaceuticals Announces European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder
-
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Marinus Pharmaceuticals Announces New Method of Use Patent Granted for IV Ganaxolone by USPTO in Status Epilepticus
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY® (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder
-
Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.
-
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023
-
Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome
-
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2022 Financial Results on March 7, 2023
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
-
Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 ZTALMY® Net Product Revenue and Provides Business Update
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Marinus Pharmaceuticals Announces Presentations and Investor Event at American Epilepsy Society 2022 Annual Meeting
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Back to MRNS Stock Lookup
